Zobrazeno 1 - 10
of 26
pro vyhledávání: '"N. H. Hendrikse"'
Autor:
E. A. van de Stadt, M. Yaqub, A. A. Lammertsma, A. J. Poot, P. R. Schober, R. C. Schuit, E. F. Smit, I. Bahce, N. H. Hendrikse
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-9 (2020)
Abstract Introduction Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as afatinib. Tumour uptake of [18F]afatinib using positron
Externí odkaz:
https://doaj.org/article/ff974949073d42cfa4ad11a0d33b757f
Autor:
I. H. Bartelink, E. A. van de Stadt, A. F. Leeuwerik, V. L. J. L. Thijssen, J. R. I. Hupsel, J. F. van den Nieuwendijk, I. Bahce, M. Yaqub, N. H. Hendrikse
Publikováno v:
Pharmaceuticals, Vol 15, Iss 7, p 796 (2022)
Introduction: Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR overexpression and mutation in NSCLC can be determined using radiolabeled EGFR T
Externí odkaz:
https://doaj.org/article/4a3c1f606e5e4050bc8e7a6d4205fd79
Autor:
A. N. Niemeijer, D. Leung, M. C. Huisman, I. Bahce, O. S. Hoekstra, G. A. M. S. van Dongen, R. Boellaard, S. Du, W. Hayes, R. Smith, A. D. Windhorst, N. H. Hendrikse, A. Poot, D. J. Vugts, E. Thunnissen, P. Morin, D. Lipovsek, D. J. Donnelly, S. J. Bonacorsi, L. M. Velasquez, T. D. de Gruijl, E. F. Smit, A. J. de Langen
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-5 (2018)
Assessment of PD-1 and PD-L1 expression can be predictive of immunotherapy response in lung cancer. Here the authors assess the clinical toxicity, safety and quality of non-invasive imaging of PD-1 and PD-L1 expression in 13 patients with advanced lu
Externí odkaz:
https://doaj.org/article/d775b429652c43478095f6b7bc6015c1
Autor:
Sabrine Q. Kol, Ruth S. Smit, Ben G.J.C. Zwezerijnen, B. Windhorst, B.H.E. Jansen, Maqsood Yaqub, Harry N. H. Hendrikse, Dennie Meijer, Katelijne de Bie, Patrick J. van der Voorn, André N. Vis, Yves J. L. Bodar, Daniela E. Oprea-Lager
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging, 49(5), 1731-1742. Springer Verlag
Bodar, Y J L, Zwezerijnen, B G J C, van der Voorn, P J, Jansen, B H E, Smit, R S, Kol, S Q, Meijer, D, de Bie, K, Yaqub, M, Windhorst, B A D, Hendrikse, H N H, Vis, A N & Oprea-Lager, D E 2022, ' Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI : a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. 5, pp. 1731-1742 . https://doi.org/10.1007/s00259-021-05604-9
Bodar, Y J L, Zwezerijnen, B G J C, van der Voorn, P J, Jansen, B H E, Smit, R S, Kol, S Q, Meijer, D, de Bie, K, Yaqub, M, Windhorst, B A D, Hendrikse, H N H, Vis, A N & Oprea-Lager, D E 2022, ' Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI : a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. 5, pp. 1731-1742 . https://doi.org/10.1007/s00259-021-05604-9
Purpose Multiparametric magnetic resonance imaging (mpMRI) is a well-established imaging method for localizing primary prostate cancer (PCa) and for guiding targeted prostate biopsies. [18F]DCFPyL positron emission tomography combined with MRI (PSMA-
Autor:
Y J L, Bodar, W I, Luining, B, Keizer, D, Meijer, A, Vellekoop, M, Schaaf, N H, Hendrikse, R J A, Van Moorselaar, D E, Oprea-Lager, A N, Vis
Publikováno v:
Urologic oncology.
Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is an emerging staging tool for patients with primary high-risk prostate cancer (PCa). Patients with primary metastatic disease are staged using PSMA-
Autor:
Yves J L, Bodar, Ben G J C, Zwezerijnen, Patrick J, van der Voorn, Bernard H E, Jansen, Ruth S, Smit, Sabrine Q, Kol, Dennie, Meijer, Katelijne, de Bie, Maqsood, Yaqub, Bert A D, Windhorst, Harry N H, Hendrikse, André N, Vis, Daniela E, Oprea-Lager
Publikováno v:
European journal of nuclear medicine and molecular imaging. 49(5)
Multiparametric magnetic resonance imaging (mpMRI) is a well-established imaging method for localizing primary prostate cancer (PCa) and for guiding targeted prostate biopsies. [Thirty prospectively included patients with intermediate to high-risk PC
Autor:
Egbert F. Smit, Mohammed Yaqub, E. A. van de Stadt, Idris Bahce, N. H. Hendrikse, Robert C. Schuit, Patrick Schober, Adriaan A. Lammertsma, Alex J. Poot
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-9 (2020)
EJNMMI Research, 10(1). SPRINGER
van de Stadt, E A, Yaqub, M, Lammertsma, A A, Poot, A J, Schober, P R, Schuit, R C, Smit, E F, Bahce, I & Hendrikse, N H 2020, ' Quantification of [ 18 F]afatinib using PET/CT in NSCLC patients : a feasibility study ', EJNMMI Research, vol. 10, no. 1, 97 . https://doi.org/10.1186/s13550-020-00684-4
EJNMMI Research, 10(1):97. Springer Berlin
EJNMMI Research, 10(1). SPRINGER
van de Stadt, E A, Yaqub, M, Lammertsma, A A, Poot, A J, Schober, P R, Schuit, R C, Smit, E F, Bahce, I & Hendrikse, N H 2020, ' Quantification of [ 18 F]afatinib using PET/CT in NSCLC patients : a feasibility study ', EJNMMI Research, vol. 10, no. 1, 97 . https://doi.org/10.1186/s13550-020-00684-4
EJNMMI Research, 10(1):97. Springer Berlin
Introduction Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as afatinib. Tumour uptake of [18F]afatinib using positron emission
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::724defbc8d305433c69cf6f02c8056e9
https://hdl.handle.net/1887/3184851
https://hdl.handle.net/1887/3184851
Autor:
E A, van de Stadt, M, Yaqub, A A, Lammertsma, A J, Poot, P R, Schober, R C, Schuit, E F, Smit, I, Bahce, N H, Hendrikse
Publikováno v:
EJNMMI Research
Introduction Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as afatinib. Tumour uptake of [18F]afatinib using positron emission
Publikováno v:
van de Stadt, E A, Yaqub, M, Bahce, I & Hendrikse, N H 2020, ' ABCG2-and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib : Clinical Implications in the Treatment of Central Nervous System Metastases ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 61, no. 2, pp. 305 . https://doi.org/10.2967/jnumed.119.235705
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 61(2)
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 61(2)
TO THE EDITOR: We read with great interest the article by Bauer et al. titled “A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood–Brain Barrier.” They concluded that ABCB1 inhibition by tariquidar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f993da760f9f0dc09ddf6fef6cfca3a3
https://research.vumc.nl/en/publications/e20a4351-25fd-4f8c-b3c1-2b57a6520eff
https://research.vumc.nl/en/publications/e20a4351-25fd-4f8c-b3c1-2b57a6520eff
Autor:
J. Van Moorselaar, P. Van Der Voorn, D.E. Oprea-Lager, André N. Vis, Harry N. H. Hendrikse, Y.J.L. Bodar, Ben G.J.C. Zwezerijnen, B.H.E. Jansen, Jakko A. Nieuwenhuijzen
Publikováno v:
European Urology Supplements. 18:e3377-e3378